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The sense of taste is responsible for the detection and ingestion of food to cover
energetic requirements in health and disease. The change in taste perception might lead
to malnutrition that is usually one of the frequent causes of morbidity and mortality in
patients with cancer. In this review, we summarize the mechanisms of taste perception
and how they are altered in cancer. We also address the question of the implication of
inflammation, responsible for the alterations in taste modalities. We highlight the role of
radio- and chemotherapy in the modulation of taste physiology. Other several factors
like damage to taste progenitor cells and disruption of gut microbiota are also dealt with
relation to taste perception in cancer. We further shed light on how to restore taste acuity,
by using different preventive methods, dietary modifications and pharmacotherapy in
subjects with advanced cancer state.
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INTRODUCTION
The dietary habits are governed, in part, by oro-sensory detection of taste. In fact, the taste of
nutrients leads human beings to decide quickly to accept or reject a food. Basically, there are
five taste modalities, i.e., sweet, sour, bitter, salty, umami and perhaps, a sixth fat taste (Heinze
et al. (2015). Beside the fact that taste is essential for life because it regulates food intake, taste
also provides hedonic pleasure from eating. The taste perception also activates neuronal pathways,
leading to the preparation for digestion, absorption, and storage of nutrients (Brondel et al., 2013).
A dysfunction of taste perception (dysgeusia) may impair the quality of life by affecting appetite,
body weight, and psychological well-being (Deems et al., 1991). There are several factors that
may affect taste perception, including medication, nutrition, lesions in the oral mucosa, prolonged
exposure to radiations and chemotherapy, smoking, chronic hepatitis, renal dysfunction, aging, and
perturbation in hormonal secretions (Maffeis and Silva-Netto, 1989).
Changes in taste perception are especially important in diseases like cancer, which is one of the
main causes of morbidity and mortality throughout the world. Altered taste perception in cancer
subjects is usually ignored by clinicians as this aspect does not represent the life-threatening events.
There are some indications that taste alteration might be an alarming early sign of tumor cell
invasion in cancer patients (Sherry, 2001). Indeed, the most distressing symptom in patients with
advanced cancer is gastrointestinal abnormalities, whereas the change in taste is the fourth most
common symptom after dry mouth, weight loss, and early satiety (Komurcu et al., 2002). Some
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studies suggests that 15 to 100 percent of cancer patients may
suffer from a taste change (Lockhart and Clark, 1989; Ripamonti
et al., 1998).
MECHANISM OF TASTE PERCEPTION
Before discussing the relationship between cancer and taste
changes, we must have an idea of oro-sensory perception of
taste. Taste is a complex entity that interacts with other senses:
Hearing, touch, smell, and vision. All the information from the
sensory organs is finally analyzed by the central nervous system
(CNS). During mastication, foods is mixed with saliva which is
secreted by mandibular, sublingual, and parotid salivary glands.
Saliva dilutes and disseminates palatable molecules to the taste
receptors on the tongue, palate, larynx, pharynx, and the upper
third of the esophagus (Matsuo, 2000). Taste receptors or taste
receptor cells (TRCs) have been identified on tongue epithelium
and throughout the digestive tract (Rozengurt and Sternini,
2007), but we will not discuss the latter part in this review article.
Human beings have around 5,000 taste buds. Of these, 30%
are in the fungiform papillae, 30% in foliate papillae and 40% in
circumvallate papilla (Suzuki, 2007). The filiform papillae contain
no taste buds. Goblet or circumvallate buds are located in the
posterior position of the tongue forming an inverted "V" which
are nine in humans. The foliate papillae are located in posterior
lateral position of the tongue. The fungiform and filiform papillae
are present on the apical surface of the tongue. Each taste
bud contains 50–100 taste cells, surrounded by supporting cells
which are renewed after every 10 days (Wakisaka, 2005). The
localization of taste buds and TRCs on human tongue are
shown in Figure 1. Three cell types have been identified, based
on morphological criteria (Takeda and Hoshino, 1975). Glial
or Type I cells that assure homeostasis in the taste bud, are
sensitive to salty substances and possess ATPase activity (Bartel
et al., 2006), which is crucial to degrade high concentrations
of extracellular ATP. The TRCs or type II cells are sensitive to
sweet, bitter and umami substances via the receptor activation of
T1R and T2R family. These cells secrete ATP in the interstitial
medium through pannexin channel (Romanov et al., 2008). The
ATP binds to the P2Y receptors on the presynaptic or type
III cells. This mechanism results in the release of serotonin,
thus activating the postsynaptic receptors which are involved
in the transmission of the taste information to brain. The
type III cells are sensitive to acidic substances (Yang et al.,
2000; Brondel et al., 2013; Roland and and Rémi, 2013). The
fourth type of taste cells are termed as type IV cells which
are basal, non-polarized, presumably undifferentiated cells and
serve as progenitor cells for other three types of taste cells
(Miura et al., 2006). The comprehensive reviews on different
taste modalities and the activation of different brain areas can
be consulted elsewhere (Bermúdez-Rattoni, 2004; Chaudhari and
Roper, 2010; Roper, 2013; Besnard et al., 2016). However, in brief,
we would like to outline the implication of TRCs in different
taste perception. Salt activates sodium channels, while the acidic
compounds induce the depolarization via by blocking potassium
channels (Kinnamon et al., 1988). Sweet, bitter, fat, and umami
taste involve metabotropic receptors (Medler, 2011). CD36 and
GPR120 play non-overlapping roles during orosensory detection
of dietary fats (Ozdener et al., 2014). Two large families of
receptors have been identified: T1R and T2R. The T2R receptors
are involved in the perception of bitter taste (Chandrashekar
et al., 2000). The heterodimeric T1R2/T1R3 detects the sweet
taste (Montmayeur et al., 2001), whereas the heterodimeric
T1R1/T1R3 is sensitive to umami taste (Chaudhari et al., 2000).
The binding of sapid molecules to these taste receptors activates
a G-protein, called Gustducin (Wong et al., 1996). The alpha-
subunit of gustducin activates the PLCβ2and generates inositol-
trisphosphate (IP3) and diacylglycerol. All these intracellular
mechanisms lead to an increase in intracellular calcium and
neurotransmitter release. A diagrammatical representation of
various types of taste cells and receptors involved in taste
perception are presented in Figure 2. The neurotransmitters
released by the TRC activate the afferent nerve fibers that carry
taste information to the CNS. These afferent nerves are: (i) the
cord of the eardrum (gustatory branch of the facial nerve) which
connects the fungiform papillae of the anterior two thirds of the
tongue, (ii) the glossopharyngeal nerve (IX) that connects the
goblet buds in the posterior third, and (iii) the superior laryngeal
vagus nerve (nerve X) that transmits oropharyngeal sensitivity.
Other nerves, such as the trigeminal nerve, are also incidentally
involved in taste perception. Neurons conduct a first relay in
the solitary nucleus, located in the dorsolateral part of the bulb,
and then make a second relay in the ventromedial nucleus of
the thalamus before they project into the cortical or other area,
involved in identifying taste (type and intensity). The nucleus
accumbens and the ventral tegmental area are also activated
following food ingestion. They are involved in hedonic responses
(pleasure) and the reward circuit (Kettaneh et al., 2002; Brondel
et al., 2013; Roland and and Rémi, 2013).
CANCER: INFLAMMATION AND TASTE
ALTERATIONS
One of the striking features of advanced cancer is the
inflammatory state that is generally associated with an infection
(Coussens and Werb, 2002). Rapidly proliferating cancer cells
release a number of cytokines/chemokines which favor the
recruitment of macrophages and neutrophils, which, in turn,
produce a series of cytokines and cytotoxic mediators including
prostaglandins (Kuper et al., 2000). It is mention worthy that 15%
of cancer are associated with an infection that might trigger a
sustained inflammatory state (Kuper et al., 2000). In neck cancer,
the level of pro-inflammatory cytokines, i.e., IL-1α, RANTES,
MIG, G-CSF, GM-CSF, INF-γ, TNF-a, IL-17, IL-4, IL-6, and
IL-10, in the body is increased by several fold (Johnson et al.,
2014). The cytokines like IL-12 and IFNγ have an anti-tumor
role, while the cytokines like IL-6, IL-17, and IL-23 are pro-
tumor (Lin and Karin, 2007). The cytokines IL-6 and IL-10 are
associated with poor prognosis in all types of cancer (Lippitz,
2013). Inflammation plays a crucial role in cachexia (Epstein
and Barasch, 2010). Conversely, cancer cachexia is associated
with an increase in blood levels of C-reactive protein, cytokines
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FIGURE 1 | Human taste system: (A) Localization of different types of gustatory papillae onto the human tongue. (B) Enlarged section of circumvallate papillae
showing taste bud cells.
(interleukin 1b, interleukin-6, TNF-α, and leukemia inhibitor
factor, LIF) and other tumor derived factors like lipid mobilizing
factor (LMF) and protein mobilizing factor (PMF). The LMF
and PMF can directly mobilize fatty acids and amino acids,
respectively, from adipose tissue and skeletal muscle. Ming-Hua
et al. (2016) have recently confirmed that high concentrations
of IL-1b, IL-6, TNF-α, and LMF are directly involved in cancer
cachexia. Indeed, LMF initiates ubiquitin-dependent catabolic
pathway and contributes to weight loss during cancer cachexia
(Dimitriu et al., 2005) which is, somehow, associated with loss
of taste perception as demonstrated by Maschke et al. (2017).
The inflammatory markers via blood circulation may also exert
their action in the brain and modulate the areas involved
in the control of feeding behavior including smell and taste
perception (Argilés et al., 2014). These observations suggest
that alteration in taste in cancer patients might be controlled
both at taste bud and brain levels. As regards the association
between inflammation and taste bud dysfunction that might
result into altered taste perception, we can cite the study of Wang
et al. (2009). These investigators have reported the expression
of Toll-like receptors (TLRs), type I and II interferon (IFN)
receptors, and their downstream signaling components in taste
tissue. Some TLRs appear to be selectively or more abundantly
expressed in taste buds than in non-gustatory lingual epithelium.
Immunohistochemical observations have confirmed the presence
of these receptor proteins in taste bud cells, of which TLRs 2, 3,
and 4 are expressed in type II cells. Administration of TLR ligands
and lipopolysaccharides activated IFN-g signaling pathways, up-
regulated the expression of IFN-g-inducible genes, and down-
regulated the expression of c-fos in taste buds. Interestingly,
systemic administration of IFNs triggered apoptosis of taste bud
cells in mice and, consequently, contributed to the development
of taste disorders. It has been shown that MRL/lpr mice have
a high concentration of IFNγ and TNF-a, and INFγ would
induce the apoptosis of TRCs. The perception of bitter, sweet
and umami taste is also reduced in these mice. This alteration
of taste perception is associated with a decrease in the number of
gustducin positive cells and renewal of TRCs (Kim et al., 2012).
There also seems a relationship between inflammation and
hyperglycemia in cancer since carbohydrate metabolism is
altered in cancer patients (Duan et al., 2014), as is the case
of type 2 diabetes. The high glucose metabolism in cancer
cells might be due to high expression of glucose transporters
(Walenta et al., 2000; Hauptmann et al., 2005). Gondivkar et al.
(2009) have reported that the subjects with type 2 diabetes
may also suffer from alterations in taste thresholds for different
taste modalities. Hence, it is possible that the alteration in
carbohydrate metabolism and taste perceptionmay be a common
mechanism between type 2 diabetes and cancer. However, this
statement requires further studies in future.
MODIFICATION OF MICROBIOTA AND
TASTE ALTERATIONS IN CANCER
Roughly, there are ∼1014 microbes residing in human intestine
with genetic content almost 100 times higher than that of
the human genome (Ley et al., 2006). These microbiota are
present throughout the gastrointestinal tract, starting from
mouth till the terminal part of large intestine (Rozengurt
and Sternini, 2007). Schmidt et al. (2014) have shown that
the abundance of oral microbiota was varied in individuals
during oral cancer. In another study, it was observed that
some bacterial species in the buccal cavity of patients with
oral squamous cell carcinoma differed from that of normal
volunteers (Mager et al., 2005). Interestingly, the chnages in
gut microbiota are closely related with alterations in taste
preference in mice (Duca et al., 2012; Swartz et al., 2012).
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FIGURE 2 | Intercellular communications involved in taste perception. Receptors for sweet, umami, fat, and bitter taste are expressed on type-II cells while
type III cells express receptors for sour taste and type-I cells are believed to be involved in salt taste perception. Binding of tastants (1) on type-II and type-III cells
ultimately leads to an increase in intracellular calcium levels (2). ATP is excreted by type-II(3) cells which binds with P2Y receptors on type-III cells (4) and causes the
release of 5-HT (5). 5-HT causes afferent nerve endings to carry taste message to specific brain areas on one side (5), and other the other side, causes feedback
inhibition of ATP release (6). Excess ATP is also degrades by ATPase present on type-I cells (not shown). Type IV cells are progenitor cells that differentiate into other
three types of cells. (ATP, adenosine triphosphate; 5-HT, 5-hydroxytryptamine or serotonin).
One possible mechanism might be that the modifications of
gut microbiota might influence the expression of gut G-protein
coupled receptors (Rousseaux et al., 2007), beside manipulating
host feeding behavior through hormonal and neural mechanisms
(Alcock et al., 2014). Oral mucositis, which is closely related
with alterations in taste, is frequently reported in cancer patients
undergoing chemotherapy (Knox et al., 2000). Wang et al.
(2015) have proposed that disruption of oral microbiota could
result in chemotherapy-induced inflammation through toll-
like receptors (TLRs) and nucleotide oligomerization domain
(NOD)-like receptors (NLRs). Ligands for these receptors like
peptidoglycan, lipopolysaccharide, bacterial DNA, and protein
flagellin are frequently provided by disrupted microbiota, which
results in induction of inflammatory process. As cancer therapy is
frequently associated with disruptedmicrobiota, while alterations
of microbiota leads to inflammation and changes is taste
perception, it would be natural to assume that disruption of
gut microbiota might result in taste changes in cancer patients.
However, this argument needs to be studied in future.
CANCER THERAPY AND CHANGES IN
TASTE
Chemotherapy
Chemotherapy may affect the taste perception (Berteretche
et al., 2004; Rehwaldt et al., 2009). In a study conducted on
cancer patients undergoing chemotherapy, the prevalence of
taste alterations was reported to be as high as 69.9%, and a
significant association was found between taste alterations and
a change in patient’s quality of life such as appetite and fatigue
(Zabernigg et al., 2010). In a study, performed on pediatric
patients, undergoing chemotherapy, the altered taste perception
caused problems in feeding behavior (Skolin et al., 2006). It
was suggested that changes had occurred both in the primary
gustatory sense as well as in food perception in these patients.
Taste-test showed that these patients had increased thresholds
for bitter taste (Skolin et al., 2006). Such changes in taste
may be resolved within several months after the completion of
chemotherapy (Bernhardson et al., 2007). Zinc is an important
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micronutrient which also plays a role in the perception of taste.
Studies suggest that Zinc depletion is closely related to a change of
taste in cancer patients (Heyneman, 1996; Yamagata et al., 2003).
A possible mechanism by which the drugs treating cancer could
cause Zinc deficiency may involve the binding and chelation
of Zinc and other heavy metals by sulfhydryl group in their
structures, leading to Zinc depletion and loss of taste (Comeau
et al., 2001).
Radiation Therapy
Taste disorders are quite frequent in patients undergoing
radiation therapy for head and neck cancers (Zheng et al., 2002).
In a study, it was reported that bitter taste was the most affected
taste, while sweet taste was affected to a lesser extent (Zheng et al.,
2002). Another study showed that bitter and salty taste were the
earliest and the most affected taste modalities, while sweet taste
was the least affected as a result of radiation therapy (Mossman
and Henkin, 1978). Taste impairment may start a few weeks after
the beginning of radiation treatment, while it may recover to its
previous levels 6 months to 1 year after the treatment has been
stopped but some patients may suffer from permanent loss of
taste (Ruo Redda and Allis, 2006). Impairment of ummami taste
as a result of radiation therapy in cancer patients has also been
reported (Shi et al., 2004). Changes in taste are mainly due to the
damage caused by radiation field to taste cells and the pattern
of the taste disorder is heavily influenced by the distribution of
the taste buds damaged during the radiation therapy (Yamashita
et al., 2006). Also, radiation and chemotherapy induce apoptosis
of TRCs and inhibit taste progenitor/stem cell proliferation. Role
of dry mouth (xerostomia) has also been implicated as a factor
contributing to taste change, as radiation therapy frequently
affects saliva quantity and composition (Mossman and Henkin,
1978) by damaging salivary glands. A brief summary of the
factors that result in taste change has been shown in Figure 3.
Plausible Effect of Radio- and
Chemotherapy on Taste Progenitor Cells
Radiation or chemotherapy might target both taste progenitor
as well as already existing taste cells. How these treatments
affect differentiation or reduce the cell number by targeting
apoptotic or particular pathways are poorly understood. There
are pathways known for differentiation of taste bud cells such
as sonic hedgehog (SHH) and notch pathways (Kapsimali and
Barlow, 2013) which are modulated during cancer (Merchant
and Matsui, 2010). In particular, SHH is exclusively expressed
in type IV taste cells, which are undifferentiated basal cells and
the precursors of the other three types of taste cells (Miura
et al., 2006). Use of SHH pathway inhibitor, Vismodegib, in
cancer patients is often associated with profound alterations in
taste sensation (Von Hoff et al., 2009; Sekulic et al., 2012; Tang
et al., 2012). Yang et al. (2015) have shown that Vismodegib
treatment in mice resulted in an altered taste perception.
Significant reductions in taste bud size, numbers of taste cells
per taste bud, and numbers of SHH-expressing cells in taste bud
were also observed in these mice. Furthermore, the numbers
of phospholipase Cβ2- and α-gustducin- T1R3, glucagon-like
peptide-1, and glucagon-expressing cells were also reduced in
the taste bud of these mice. Similar findings were observed by
Kumari et al. (2015), who reported that the blockade of hedgehog
pathway by cancer drug LDE225 resulted in the disruption
of taste cells and taste perception in mice. All these findings
suggest that modulation of SHH by cancer therapy might also be
implicated in taste alterations in cancer patients.
Miura and Barlow (2010) have proposed that in head and neck
cancer patients, taste bud progenitors are more vulnerable to
FIGURE 3 | Factors contributing to alterations in taste perception in cancer. (TRCs, taste receptor cells; TBCs, taste bud cells).
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the effect of fractionated radiotherapy as compared to terminally
differentiated taste cells. They have compared this model with
irradiated skin epithelium, where proliferating skin cells are more
prone to radiation induced DNA damage than the post-mitotic
cells. Following irradiation, the progenitor cells try to repair
damaged DNA, and if they fail, they start apoptosis. Repeated
irradiation causes increased loss of progenitor cells (Dörr et al.,
2000; Potten et al., 2002). As chemotherapy also targets rapidly
dividing cells, consequently, taste alterations are observed in
patients undergoing chemotherapy for non-head/neck cancers as
well.
MEASUREMENT OF TASTE IMPAIRMENT
AND DETECTION THRESHOLD IN CANCER
Different methods have been used for the measurement of
taste impairment and detection thresholds in cancer patients.
A detailed account of the methods will be out of scope of this
article; hence, only a brief summary has been given. An electro-
gustometer can be used for the detection of taste thresholds
(Williams and Cohen, 1978). One electrode is the tongue
electrode, while the other reference electrode is placed on dorsal
side or the wrist. Electrical current is applied in different steps
and the lowest current intensity, perceived by the subject, is taken
as the detection threshold (Berteretche et al., 2004). Chemical
detection involves using tastant solution with suprathreshold
concentrations for each of the basic taste modalities (Trant et al.,
1982; Bossola et al., 2007). The subject’s mouth is rinsed with
a sip of distilled water prior to testing each sample (Sánchez-
Lara et al., 2010). The lowest concentration of solute at which
the individual consistently recognizes the taste is considered as
taste threshold (Gallagher and Tweedle, 1983; Steinbach et al.,
2009). A 3-armed forced choice (3-AFC) method can be applied
tomonitor the subject’s response for detection and reorganization
of taste (Mossman and Henkin, 1978). Subjects can be asked to
place a cross-hatch on a 10-cm line labeled at each end (0 =
dislike extremely, no sweetness, sourness, saltiness, or bitterness,
and 10 = like extremely, extremely sweet, sour, salty, or bitter)
to indicate degree of liking and intensity of each sample (Trant
et al., 1982). Alternatively, a scale ranging from 0 (total taste
loss) to 3 (no taste loss) can be employed to classify the subjects,
depending upon if they recognize no or all concentrations of
a particular taste (Maes et al., 2002). Questionnaires have also
been used by different researchers to determine the patient’s self-
reported taste changes and their effects on their quality of life
(Chencharick and Mossman, 1983; Huldij et al., 1986; Bjordal
et al., 1994; Bernhardson et al., 2008). The choice of a particular
test depends on the practitioner.
SELF-CARE STRATEGIES BY PATIENTS TO
MINIMIZE ALTERATIONS IN TASTE
The patients themselves can assess the changes in thresholds for
different taste modalities. Consequently, they may change either
their feeding habits or adopt appropriate palatable strategies.
For example, breast cancer patients, undergoing docetaxel or
paclitaxel chemotherapy, included a number of strategies like
changing food habits by adding new recipes (Speck et al., 2013).
Wickham et al. (1999) proposed to increase food palatability by
adding artificial falvours. Rehwaldt et al. (2009) have reported
that each patient should have its own particular strategy to
adapt taste alterations. Hence, more than 50% of the patients
reported that they tried selected one of the following strategies:
More fats and sauces, eating smaller and more frequent meals,
using more condiments, eating blander foods, adding something
sweet to meats, sucking on hard candy, eating more boiled
foods, and avoiding beef. These strategies were helpful for the
majority (74–87%) of patients who tried them. Nonetheless, self-
care strategies are difficult to be practized due to psychological
constraints.
PREVENTION AND TREATMENT OF TASTE
ALTERATIONS
Patient counseling can be started in advance to prepare patient
mentally before time. Rhodes et al. (1994) have demonstarted
if the patients are prepared psychologically for taste alterations,
they can tolerate taste changes easily. Ravasco et al. (2003) have
stressed on counseling the cancer patients to face the altered
changes in taste perception. Before chemotherapy, the patients
can be encouraged to try new food products or supplements
(Capra et al., 2001). Lemon juice and chewing gum could
be used prior to meals to make the meals more pleasant.
Small but frequent meals should be encouraged as they are
better tolerated by the patients (Ravasco, 2005). Patients can
also be asked to maintain good oral hygiene as it may also
contribute to changes in taste. To assess whether changes in
taste perception in cancer patients are causing taste aversion
and, consequently, to malnutrition, the clinicians may use
different approaches, likeMalnutrition Screening Tool (Ferguson
et al., 1999), Interdisciplinary Nutrition Care Plan (Capra et al.,
2001), or the Patient-Generated Subjective Global Assessment
(Ferguson, 2003). A close contact and relationship between
health care professionals and patients is highly desirable in order
to assess the nutritional status and improve the quality of life of
the patients.
Zinc supplementation can be valuable for patients undergoing
cancer chemotherapy. The results of a pilot study suggested that
after 2 weeks of chemotherapy, the intake of Zinc protected
the cancer patients against taste disorders (Yamagata et al.,
2003). In another study, a Zinc containing formulation known
as Polaprezinc was able to improve the taste alterations in 70
percent of the patients, though an early administration has
been suggested (Mizukami et al., 2016). Furthermore, the results
of a randomized and controlled clinical trial on the effects of
Zinc sulfate have clearly demonstrated that exogenous Zinc
improved taste acuity (Ripamonti et al., 1998). Similar findings
were observed in a randomized placebo-controlled trial where
Zinc sulfate prevented the radiation-induced taste changes in
head/neck cancer patients (Najafizade et al., 2013). Halyard et al.
(2007) conducted a clinical study on Zinc sulfate vs. placebo
and concluded that intake of Zinc offered protection against
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alterations in taste modalities. Hence, the routine use of Zinc
sulfate may be suggested for patients undergoing cancer therapy.
Amifostine, an organic thiophosphate, has been shown to
protect normal tissues from damage caused by radiation and
chemotherapy (Kouvaris et al., 2007). Amifostine may also play
a role in the protection of salivary glands and, thus leading
to improvement of xerostomia. In a phase II randomized trial,
amifostine has been used to assess protection against the toxic
effects of carboplatin (Bohuslavizki et al., 1998). Münter et al.
(2007) also came to the similar conclusion that amifostine may
prevent reduced salivary gland function in patients, subjected to
radiotherapy.
The efficacy of two drugs, i.e., pilocarpine and bethanechol,
that increase production of saliva was tested upon saliva secretion
in cancer patients with hypo-salivation following radiation
therapy (Gorsky et al., 2004). Though the patients reported
improvement in saliva secretion by both the agents, only
bethanechol improved taste perception.
A pilot investigation was conducted to assess the role of
serotonergic blockade by using ondansetron, an antagonist of
serotonin type-3 receptor (Edelman et al., 1999). This study
included metastatic cancer patients who were not undergoing
chemotherapy or radiotherapy. Utilizing an “extensive battery
of taste tests,” it was concluded that ondansetron brought
about significant improvements in patients to enjoy food. A
major drawback in this study was that it was not a blinded
trial, and, hence, placebo effects could not be fully excluded
(Edelman et al., 1999). Moreover, it was not clear whether the
enhanced enjoyment from eating was due to improvements in
taste. In rodent model, it seems that 5-HT acts as a paracrine
inhibitory feedback signal manifested by the inhibition of ATP
secretion from TRCs. Taste buds express 5-HT1A receptor and
the use of its specific agonist, 8-OH-DPAT, inhibited taste-
evoked Ca2+ release in TRCs and also curtailed ATP release.
Conversely, blocking the action of endogenous 5-HT in taste
bud cells by using WAY100635, a selective 5-HT1A receptor
antagonist, increased taste-evoked ATP release (Huang et al.,
2009). However, in-depth studies aiming to reproduce the afore-
mentioned observations in humans are awaited.
FUTURE PROSPECTS
The pathophysiology of taste alterations differs with relation to
the phase of the disease and specific treatment. Unfortunately,
this aspect has been ignored in most of the publications.
Researchers should take into account the therapy and stages
of disease while collecting the data so that more specific
patient care protocols can be devised in order to minimize
the effect of a change in taste on patient’s quality of life.
Manufacturers must take into account the taste alterations that
frequently accompany cancer and should design and provide
food supplements accordingly to make them more palatable. An
interesting idea can be to develop “taste enhancers” which, once
added to food, could enhance its palatability by acting as agonist
at specific taste receptor. Such agonists can be developed for each
tastemodality. After identification of particular taste impairment,
the enhancers for that taste can be added to make food more
pleasurable for patients.
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